Haoxi Health Technology LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Haoxi Health Technology Limited reported a significant 32% revenue decrease and a 66% gross profit drop for fiscal year 2025, despite a rise in net income driven by non-operating gains.
NASDAQ
20-F: Haoxi Health Technology Limited Files 20-F Annual Report, Details Financials and Operational Risks
Haoxi Health Technology Limited files its 20-F annual report, outlining its financial performance, business operations, and associated risks, particularly those related to operating in China.